Story
Carl Zeiss Meditec Revenue Dips on China Weakness, Margin Pressure

Carl Zeiss Meditec reported a decline in revenue and a significant contraction in profit margins for the first nine months of its fiscal year, weighed down by currency headwinds and persistent challenges in the Chinese market. The medical technology company announced on Thursday that it now anticipates a goodwill impairment charge in its Ophthalmology business unit.
Performance Details
For the nine-month period, Carl Zeiss Meditec's revenue fell 2.9% to €1.55 billion, according to the company's disclosure. On a currency-adjusted basis, revenue was flat compared to the prior-year period.
The company's profitability saw a more pronounced decline. The adjusted EBITA margin contracted to 8.0%, down from 11.1% a year earlier. This was attributed to negative currency effects and lower sales of consumables.
China and Ophthalmology Headwinds
The primary driver of the weaker results was the company's ophthalmology segment, which faced several challenges, particularly in China. The company cited a decrease in demand and the withdrawal of a bifocal intraocular lens from a procurement tender, which led to inventory returns and weakened its lens business in the country.
AdFurthermore, the refractive laser business experienced a slowdown due to lower procedure volumes and a more cautious investment environment for new equipment, especially in the Asia-Pacific region. In a contrasting bright spot, the microsurgery unit registered growth, supported by strong deliveries of neurosurgical operating microscopes.
Updated Outlook and Impairment
Looking ahead, Carl Zeiss Meditec provided guidance for the full fiscal year 2025/26, forecasting revenue between €2.15 billion and €2.20 billion. The company expects its adjusted EBITA margin to be in the range of 8% to 10% for the full year.
Reflecting the difficulties in its ophthalmology division, the company also anticipates an impairment of goodwill of approximately €150 million in the fourth quarter. This non-cash charge indicates a reduction in the estimated future value of the business unit.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.